Search
Sulfadiazine
go.drugbank.com/drugs/DB00359ApprovedInvestigationalVet approvedOne of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.
Synonyms: N(1)-2-Pyrimidylsulfanilamide, N(1)-2-PyrimidinylsulfanilamideMixtures: TMP/S-400 Medicated Premix Powder, SUFATRIM 48%w/w PremixFinasteride
go.drugbank.com/drugs/DB01216ApprovedInvestigationalIt works in a similar fashion as [dutasteride], which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. … Finasteride is a synthetic 4-azasteroid compound [L10565] and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone
Mixtures: Finasteride 0.1% / Minoxidil 7%, Finasteride 0.1% / Minoxidil 5%Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesOrphenadrine
go.drugbank.com/drugs/DB01173ApprovedInvestigationalA muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
Synonyms: N,N-dimethyl-2-[(o-methyl-α-phenylbenzyl)oxy]ethylamine, N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamineMixtures: Norgesic 35 mg/450 mg Tabletten, MYOGESIC-GLiraglutide
go.drugbank.com/drugs/DB06655ApprovedInvestigational[A6932] Liraglutide was granted FDA approval on January 25, 2010.[L6070] … Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.
Mixtures: Xultophy 100/3.6, XULTOPHY 100U/ML+3.6MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 1 ADETCategories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 AgonistsZanamivir
go.drugbank.com/drugs/DB00558ApprovedInvestigationalA guanido-neuraminic acid that is used to inhibit neuraminidase.
Synonyms: 5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid, 5-(acetylamino)-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acidCategories: Heterocyclic Compounds, 1-RingMepolizumab
go.drugbank.com/drugs/DB06612ApprovedInvestigationalEosinophils are involved in inflammatory immune responses, and prolonged hypereosinophilia (typically defined as absolute eosinophil levels of 1500/mm<sup>3</sup> or more) is associated with a spectrum … This indication was subsequently expanded to cover EGPA on December 12, 2017, and HES on September 25, 2020.[L16518]
Categories: Interleukin-5 AntagonistProducts: NUCALA 100 MG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, NUCALA 100 MG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 3 ADETLevamisole
go.drugbank.com/drugs/DB00848ApprovedInvestigationalVet approvedWithdrawn[A178117] It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations[A178123] Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. … [A178123] Interestingly, levamisole has been found as an adulterant in cocaine and can lead to a variety of adverse effects in individuals using this drug.[A178120]
Categories: Heterocyclic Compounds, 1-RingProducts: PVP- LEVAMISOLE POUR-ON SOLUTION 20 %w/v, PARAKS 40 MG/5 ML ŞURUP, 30 MLDihydrocodeine
go.drugbank.com/drugs/DB01551ApprovedIllicitIt is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis
Mixtures: Poly-tussin EX, WellTuss EXPCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPazopanib
go.drugbank.com/drugs/DB06589ApprovedInvestigationalPazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: VOTRIENT® 200 MG, VOTRIENT® 400 MGXylometazoline
go.drugbank.com/drugs/DB06694ApprovedXylometazoline works by binding to alpha (α)-adrenergic receptors to cause vasoconstriction of nasal blood vessels.
Mixtures: NASOWELL 1 MG/ML+ 50 MG/ML BURUN SPREYİ, ÇÖZELTİ, 1 ADET, Otrivin plus Dexpanthenol 1 mg/ml + 50 mg/ml Nasenspray, LösungCategories: Adrenergic alpha-1 Receptor Agonists, Heterocyclic Compounds, 1-Ring